Nov 2015

probiodrug

Joint Bookrunner

€ 13.5 million

Private Placement

Probiodrug

Probiodrug is a biopharmaceutical company dedicated to the research and development of novel therapeutic solutions to treat people with Alzheimer’s Disease

Probiodrug completed a sub-10% private placement by issuing new shares priced at market levels
Proceeds will be used for the preparations of further clinical development of its lead product PQ912
Kempen & Co’s efforts resulted in a well-covered book made up of long-term specialist investors